

Alberta Cappelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7727830/publications.pdf>

Version: 2024-02-01

64
papers

2,409
citations

257357

24
h-index

206029

48
g-index

64
all docs

64
docs citations

64
times ranked

3344
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. <i>Hepatology</i> , 2011, 54, 868-878.	3.6	550
2	Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small ($\leq 5\text{ cm}$) hepatocellular carcinomas. <i>Hepatology</i> , 2011, 53, 1580-1589.	3.6	229
3	Factors That Affect Efficacy of Ultrasound Surveillance for Early Stage Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1927-1933.e2.	2.4	108
4	Yttrium-90 radioembolization vs sorafenib for intermediate-to locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. <i>Liver International</i> , 2015, 35, 1036-1047.	1.9	94
5	Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. <i>Liver Transplantation</i> , 2010, 16, 658-667.	1.3	93
6	Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 64, 79-86.	1.8	83
7	Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 753-761.	1.8	82
8	A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 1157-1166.	1.9	70
9	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 160-168.	1.9	70
10	Refining prognosis after transarterial chemoembolization for hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 729-736.	1.9	62
11	Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. <i>British Journal of Cancer</i> , 2016, 115, 297-302.	2.9	58
12	Computed tomography-guided percutaneous abscess drainage in coloproctology: review of the literature. <i>Techniques in Coloproctology</i> , 2007, 11, 197-208.	0.8	56
13	CT-guided percutaneous pelvic abscess drainage in Crohn's disease. <i>Techniques in Coloproctology</i> , 2006, 10, 99-105.	0.8	55
14	Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study. <i>British Journal of Cancer</i> , 2014, 111, 667-673.	2.9	51
15	Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. <i>World Journal of Hepatology</i> , 2015, 7, 738.	0.8	48
16	TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 1041.	1.1	48
17	Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, 798-805.	0.4	46
18	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 423-433.	1.9	46

#	ARTICLE	IF	CITATIONS
19	Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma: A Systemic Review and Meta-Analysis. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 728-738.	0.9	44
20	Yttrium-90 Radioembolization in Unresectable Intrahepatic Cholangiocarcinoma: Results of a Multicenter Retrospective Study. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1305-1314.	0.9	41
21	Refractory Complex Crohn's Perianal Fistulas: A Role for Autologous Microfragmented Adipose Tissue Injection. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 321-330.	0.9	38
22	Improving patient selection for selective internal radiation therapy of intrahepatic cholangiocarcinoma: A meta-regression study. <i>Liver International</i> , 2017, 37, 1056-1064.	1.9	35
23	Radiomics of cholangiocarcinoma on pretreatment CT can identify patients who would best respond to radioembolisation. <i>European Radiology</i> , 2020, 30, 4534-4544.	2.3	34
24	Transjugular intrahepatic portosystemic shunt: A case report of rescue management of unrestrainable variceal bleeding in a pregnant woman. <i>Digestive and Liver Disease</i> , 2008, 40, 387-390.	0.4	29
25	Selective Internal Radiation Therapy (SIRT) as Conversion Therapy for Unresectable Primary Liver Malignancies. <i>Liver Cancer</i> , 2016, 5, 303-311.	4.2	23
26	Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2017, 104, 1704-1712.	0.1	21
27	Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediate advanced hepatocellular carcinoma. <i>Future Oncology</i> , 2015, 11, 3133-3142.	1.1	20
28	Years of life that could be saved from prevention of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 814-824.	1.9	20
29	Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 1494-1500.	0.6	19
30	Selective transarterial radioembolisation of unresectable liver-dominant colorectal cancer refractory to chemotherapy. <i>Radiologia Medica</i> , 2015, 120, 767-776.	4.7	19
31	Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1721-1730.	3.3	18
32	Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria. <i>Scientific Reports</i> , 2019, 9, 3781.	1.6	18
33	Pattern of macrovascular invasion in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13542.	1.7	18
34	Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. <i>Journal of Hepatocellular Carcinoma</i> , 2014, 1, 163.	1.8	15
35	Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma. <i>Future Oncology</i> , 2017, 13, 1301-1310.	1.1	15
36	Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study. <i>Liver Transplantation</i> , 2021, 27, 1758-1766.	1.3	15

#	ARTICLE	IF	CITATIONS
37	Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis. CardioVascular and Interventional Radiology, 2021, 44, 1048-1059.	0.9	14
38	A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. Digestive and Liver Disease, 2011, 43, 1015-1021.	0.4	10
39	FDG PET/CT for bone and soft-tissue biopsy. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1333-1334.	3.3	10
40	Balloon-Occluded Transarterial Chemoembolization: In Which Size Range Does It Perform Best? A Comparison of Its Efficacy versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching. Liver Cancer, 2021, 10, 522-534.	4.2	10
41	Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. Journal of Hepatology, 2018, 69, 259-260.	1.8	9
42	First Case of 2 Intraductal Papillary Mucinous Tumors of Both Ventral and Dorsal Ducts in Pancreas Divisum. Pancreas, 2010, 39, 110-111.	0.5	8
43	Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3058-3065.	3.3	8
44	Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 661-668.	3.3	7
45	Performance of Capsule Endoscopy and Cross-Sectional Techniques in Detecting Small Bowel Lesions in Patients with Crohn's Disease. Crohn's & Colitis 360, 2020, 2, .	0.5	7
46	Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis. CardioVascular and Interventional Radiology, 2020, 43, 1015-1024.	0.9	6
47	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. European Journal of Cancer, 2021, 158, 133-143.	1.3	4
48	Adding Liver Stiffness Measurement to the Routine Evaluation of Hepatocellular Carcinoma Resectability Can Optimize Clinical Outcome. Ultraschall in Der Medizin, 2017, 38, 515-522.	0.8	3
49	Portal Hypertensive Biliopathy in Adult Patients: Findings and Interventional Radiologic Treatment—A Single-Center Experience. Seminars in Liver Disease, 2019, 39, 502-512.	1.8	3
50	Scar Pregnancy and Extrauterine Implants. Seminars in Ultrasound, CT and MRI, 2021, 42, 46-55.	0.7	3
51	Noncontrast-enhanced MRI-based Noninvasive Score for Portal Hypertension (CHESS1802): An International Multicenter Study. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	3
52	Balloon-assisted coil embolization (BACE) of a wide-necked aneurysm of the inferior pancreaticoduodenal artery. CVIR Endovascular, 2020, 3, 62.	0.4	3
53	Reply to: "Sorafenib or ⁹⁰ Y loaded resin microsphere radioembolization for locally advanced hepatocellular carcinoma, what should we trust?" Liver International, 2015, 35, 1780-1781.	1.9	2
54	Outcomes following percutaneous treatment of biliary stones. Hpb, 2019, 21, 1057-1063.	0.1	2

#	ARTICLE	IF	CITATIONS
55	Recalibrating survival prediction among patients receiving transâ€arterial chemoembolization for hepatocellular carcinoma. Liver Cancer International, 2021, 2, 45-53.	0.2	2
56	High-flow priapism after T-shunt and tunneling in a patient with ischemic priapism. Turkish Journal of Urology, 2020, 46, 488-491.	1.3	2
57	Reply to â€œRe: Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinomaâ€”A Propensity Analysisâ€• CardioVascular and Interventional Radiology, 2021, 44, 1135-1136.	0.9	1
58	Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?. Liver Cancer, 2021, 10, 1-2.	4.2	1
59	Routine blood tests? Helping you live(r) longer!. Lancet, The, 2011, 378, 2048.	6.3	0
60	Young Women With Acute Lower Gastrointestinal Bleeding. Annals of Emergency Medicine, 2016, 68, e55-e56.	0.3	0
61	Reply to External validation of an individual prognostic calculator after transâ€arterial chemoâ€embolization for hepatocellular carcinoma. Liver International, 2016, 36, 1232-1232.	1.9	0
62	Trans-arterial embolization for hepatocellular carcinoma: with or without epidoxorubicin?. Translational Cancer Research, 2016, 5, S208-S211.	0.4	0
63	Transarterial Chemoembolisation and Combined Therapy. Medical Radiology, 2021, , 283-317.	0.0	0
64	Percutaneous abdomino-pelvic abscess drainage in complicated Crohnâ€™s disease. Annals of Clinical Gastroenterology and Hepatology, 2020, 4, 045-051.	0.1	0